Literature DB >> 8030751

Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains.

J F Aronson1, N K Herzog, T R Jerrells.   

Abstract

A guinea pig passage-adapted strain of the arena-virus Pichinde (adPIC) is highly virulent in inbred guinea pigs, whereas the related strain PIC3739 is attenuated. Both viruses were macrophage tropic and infected peritoneal, splenic, liver, and alveolar macrophages during experimental Pichinde virus infection. Infection with the virulent strain was associated with unlimited viral replication in the face of exaggerated delayed-type hypersensitivity response, manifested by the macrophage disappearance reaction. Histopathological lesions unique to adPIC-infected guinea pigs included intestinal villus blunting with mucosal infiltration by pyknotic debris-laden macrophages and apoptosis of crypt epithelial cells. Splenic red pulp necrosis was also significantly associated with adPIC infection but not PIC3739 infection. These findings may provide clues to the pathogenesis of a group of poorly understood human viral hemorrhagic fevers.

Entities:  

Mesh:

Year:  1994        PMID: 8030751      PMCID: PMC1887300     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  The pathology of human Lassa fever.

Authors:  W C Winn; D H Walker
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

2.  [Histopathological diagnosis of hepatitis due to Lassa virus].

Authors:  H Sarrat; R Camain; J Baum; Y Robin
Journal:  Bull Soc Pathol Exot Filiales       Date:  1972 Sep-Oct

3.  The macrophage disappearance reaction: mediation by a soluble lymphocyte-derived factor.

Authors:  H Sonozaki; S Cohen
Journal:  Cell Immunol       Date:  1971-08       Impact factor: 4.868

4.  Pathologic and virologic study of fatal Lassa fever in man.

Authors:  D H Walker; J B McCormick; K M Johnson; P A Webb; G Komba-Kono; L H Elliott; J J Gardner
Journal:  Am J Pathol       Date:  1982-06       Impact factor: 4.307

5.  Pichindé virus, a new virus of the Tacaribe group from Colombia.

Authors:  H Trapido; C Sanmartín
Journal:  Am J Trop Med Hyg       Date:  1971-07       Impact factor: 2.345

6.  Virus-initiated septic shock. Acute death of Venezuelan encephalitis virus-infected hamsters.

Authors:  L Gorelkin; P B Jahrling
Journal:  Lab Invest       Date:  1975-01       Impact factor: 5.662

7.  Variation between strains of hamsters in the lethality of Pichinde virus infections.

Authors:  M J Buchmeier; W E Rawls
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

8.  The effect of an arenavirus infection on liver morphology and function.

Authors:  H L Lucia; D H Coppenhaver; R L Harrison; S Baron
Journal:  Am J Trop Med Hyg       Date:  1990-07       Impact factor: 2.345

9.  Quantitative study on the production and kinetics of mononuclear phagocytes during an acute inflammatory reaction.

Authors:  R Van Furth; M C Diesselhoff-den Dulk; H Mattie
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

10.  Morphology and peroxidase cytochemistry of mouse promonocytes, monocytes, and macrophages.

Authors:  R van Furth; J G Hirsch; M E Fedorko
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

View more
  34 in total

1.  Characterization of the Glycoprotein Stable Signal Peptide in Mediating Pichinde Virus Replication and Virulence.

Authors:  Junjie Shao; Xiaoying Liu; Hinh Ly; Yuying Liang
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

2.  Genome comparison of virulent and avirulent strains of the Pichinde arenavirus.

Authors:  Shuiyun Lan; Lisa McLay; Judy Aronson; Hinh Ly; Yuying Liang
Journal:  Arch Virol       Date:  2008-05-28       Impact factor: 2.574

3.  Characterization of virulence-associated determinants in the envelope glycoprotein of Pichinde virus.

Authors:  Naveen Kumar; Jialong Wang; Shuiyun Lan; Shamika Danzy; Lisa McLay Schelde; Jill Seladi-Schulman; Hinh Ly; Yuying Liang
Journal:  Virology       Date:  2012-08-09       Impact factor: 3.616

Review 4.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

5.  Attenuated and lethal variants of Pichindé virus induce differential patterns of NF-kappaB activation suggesting a potential target for novel therapeutics.

Authors:  Gavin C Bowick; Susan M Fennewald; Lihong Zhang; Xianbin Yang; Judith F Aronson; Robert E Shope; Bruce A Luxon; David G Gorenstein; Norbert K Herzog
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

Review 6.  Comparative pathogenesis and systems biology for biodefense virus vaccine development.

Authors:  Gavin C Bowick; Alan D T Barrett
Journal:  J Biomed Biotechnol       Date:  2010-06-06

7.  Proteomic analysis of Pichindé virus infection identifies differential expression of prothymosin-alpha.

Authors:  Gavin C Bowick; Kizhake V Soman; He Wang; Judith F Aronson; Bruce A Luxon; Lee O Lomas; David G Gorenstein; Norbert K Herzog
Journal:  J Biomed Biotechnol       Date:  2010-04-18

8.  Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers.

Authors:  Shuiyun Lan; Lisa McLay Schelde; Jialong Wang; Naveen Kumar; Hinh Ly; Yuying Liang
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

9.  Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs.

Authors:  Nadezhda E Yun; Nathaniel S Linde; Natallia Dziuba; Michele A Zacks; Jeanon N Smith; Jennifer K Smith; Judy F Aronson; Olga V Chumakova; Heather M Lander; Clarence J Peters; Slobodan Paessler
Journal:  Am J Trop Med Hyg       Date:  2008-08       Impact factor: 2.345

10.  Pichinde virus induces microvascular endothelial cell permeability through the production of nitric oxide.

Authors:  Rebecca L Brocato; Thomas G Voss
Journal:  Virol J       Date:  2009-10-08       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.